Genomics of Hematologic Cancers

Dear Colleagues,

Hematologic malignancies account for 10% of all cancers around the world and have become more frequent over the past years. Despite the huge progress associated with the improvements in hematologic molecular diagnostics and the development of targeted therapies such as kinase inhibitors, monoclonal antibodies, CART-cells and bispecific antibodies, most hematologic cancers remain incurable diseases.

Applying genomic analysis based on high-throughput sequencing technologies has been rapidly expanding our understanding of cancer origin and complexity, giving us more reliable information on its progression, metastases, and survival. Genome sequencing has been provided to know a full spectrum of genetic mutations that trigger or contribute to cancer development and how cancer evolves in response to treatments.

In this way, cancer-genome profiling is currently widely applied in routine clinical practice and has enabled the detection of predictive biomarkers of response for treatment.

This Special Issue is devoted to the application of genomics in identifying new cancer targets and developing new targeted therapies in hematologic cancers.

Dr. Aneta Szudy-Szczyrek
Prof. Dr. Marek Hus
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.